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Abstract. Dystrophin plays an important role in skele- 
tal muscle by linking the cytoskeleton and the extracel- 
lular matrix. The amino terminus of dystrophin binds to 
actin and possibly other components of the subsar- 
colemmal cytoskeleton, while the carboxy terminus as- 
sociates with a group of integral and peripheral mem- 
brane proteins and glycoproteins that are collectively 
known as the dystrophin-associated protein (DAP) 
complex. We have generated transgenic/mdx mice ex- 
pressing "full-length" dystrophin constructs, but with 
consecutive deletions within the COOH-terminal do- 
mains. These mice have enabled analysis of the interac- 
tion between dystrophin and members of the DAP 
complex and the effects that perturbing these associa- 
tions have on the dystrophic process. Deletions within 
the cysteine-rich region disrupt the interaction between 
dystrophin and the DAP complex, leading to a severe 
dystrophic pathology. These deletions remove the 
[3-dystroglycan-binding  site, which leads to a parallel 
loss of both [3-dystroglycan and the sarcoglycan com- 
plex from the sarcolemma. In contrast, deletion of the 
alternatively spliced domain and the extreme COOH 
terminus has no apparent effect on the function of dys- 
trophin when expressed at normal levels. The proteins 
resulting from these latter two deletions supported 
formation of a completely normal DAP complex, and 
their expression was associated with normal muscle 
morphology in mdx mice. These data indicate that the 
cysteine-rich domain is critical for functional activity, 
presumably by mediating a direct interaction with 
[3-dystroglycan. However, the remainder of the COOH 
terminus is not required for assembly of the DAP 
complex. 
UCHENNE  muscular  dystrophy  (DMD) 1 and  the 
milder Becker  muscular  dystrophy (BMD)  are 
caused by mutations in the dystrophin gene (24). 
Although dystrophin is expressed  from a variety of pro- 
moters in a wide array of tissues, disruption of dystrophin 
function in striated muscle leads to the most devastating 
effects of these diseases (for review see reference 2). The 
complete function of the dystrophin protein in skeletal 
muscle  has  not yet been fully elucidated, although it is 
thought to provide a crucial link between the intracellular 
actin cytoskeleton and the extracellular matrix (15). The 
mdx mouse contains a nonsense mutation in the dystro- 
phin gene that leads to a complete absence of dystrophin 
in muscle, which causes a similar muscle degeneration as is 
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seen in DMD patients. As a result, the mdx mouse is a useful 
system for studying the function of the dystrophin protein. 
The full-length 427-kD dystrophin protein that is local- 
ized at the sarcolemmal membrane in skeletal muscle is of- 
ten described as consisting of four structural domains (24). 
These include an NH2-terminal  actin  binding domain, a 
central rod domain consisting  of 4 hinge regions  and 24 
units with homology to those in 13-spectrin, a cysteine-rich 
domain, and a COOH-terminal domain that contains re- 
gions of alternative splicing and two leucine zipper motifs. 
We have recently observed that expression of a full-length 
dystrophin construct deleted for the actin-binding domain 
located in exons 3-7 of the NH2 terminus improves the pa- 
thology of the mdx mouse to a mild "BMD-like" pheno- 
type (Corrado, K., and J.S. Chamberlain, manuscript sub- 
mitted for publication).  We and others have shown that 
deletion of two-thirds of the central-rod domain results in 
an almost fully functional dystrophin protein in skeletal 
muscle  of mdx mice (37, 43) Both of these observations 
correlate well with patient data (13, 44). Deletions within 
the COOH-terminal domains of dystrophin are relatively 
rare, and most of these mutations result in the absence of 
detectable dystrophin protein caused by instability at the 
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patient data relating to structure-function correlations of 
the  COOH  terminus  of dystrophin.  There  are  few  re- 
ported cases where a truncated dystrophin protein lacking 
all of the COOH-terminal domains is able to localize cor- 
rectly to the sarcolemmal membrane (5, 18, 19, 29). How- 
ever, these situations have resulted in severe DMD in pa- 
tients who are old enough for a  diagnosis. Furthermore, 
point mutations and frameshifting deletions that prevent 
translation of the dystrophin COOH terminus almost in- 
variably lead to DMD, but without detectable accumula- 
tion of a  mutant  dystrophin. These studies indicate that 
the dystrophin COOH terminus is critical for its function. 
However, patient studies have not enabled a clear descrip- 
tion of whether subregions within the COOH-terminal do- 
mains  are  important  for  stabilization  of the  dystrophin 
protein and allowing its accumulation in muscle fibers as 
opposed to playing a more direct role such as mediating 
protein-protein interactions. 
Dystrophin is known to associate with a large complex 
of integral and peripheral membrane proteins and glyco- 
proteins collectively known  as  the  dystrophin-associated 
protein (DAP) complex (34). All of the DAPs are greatly 
reduced in the skeletal muscle of DMD patients and the 
mdx mouse (16, 33). The DAPs have recently been shown 
to be composed of three subcomplexes. Laminin-2, a major 
component of the  extracellular matrix in  muscle  tissue, 
binds to a-dystroglycan, which binds directly to p-dystro- 
glycan (14).  This link to the extracellular matrix has been 
named the  dystroglycan complex. The sarcoglycan com- 
plex consisting of the integral membrane proteins c~-, p-, and 
7-, sarcoglycan is thought to associate with p-dystroglycan 
(22,  41),  although  the  exact contacts between the  com- 
plexes  have  not  been  identified.  The  third  subcomplex 
consists of one or more of the 59-kD peripheral membrane 
proteins  encoded  by  individual  yet  homologous  genes, 
known as the syntrophins 0xl, 131, and 132). cd-syntrophin 
is present uniformly around the sarcolemmal membrane 
and is thought to be present in most dystrophin complexes 
(36). pl-syntrophin is present at low levels in skeletal mus- 
cle, but its precise localization pattern has not  been re- 
ported (1). 132-syntrophin colocalizes at the neuromuscular 
junction with utrophin, and is hypothesized to associate in 
complexes with this dystrophin homologue (36). 
The identification of the primary defects for forms of 
muscular dystrophy other than DMD has provided some 
of the evidence for these subcomplexes. Limb girdle mus- 
cular dystrophies (LGMD) 2D, 2E, and 2C are caused by 
mutations in members of the sarcoglycan complex (8, 22, 
27, 28, 32). All of the members of the sarcoglycan complex 
are missing from the sarcolemmal membrane in these pa- 
tients; however, dystrophin and the dystroglycan complex 
remain correctly localized. No patient mutations have yet 
been found in the dystroglycans or the syntrophins. Re- 
cent in vitro data suggests that  p-dystroglycan binds di- 
rectly to the dystrophin cysteine-rich domain (23, 41), and 
that no other members of the dystroglycan or sarcoglycan 
complexes bind directly to dystrophin, al-syntrophin has 
been shown to bind to the portion of dystrophin encoded 
by exons 73 and 74 in vitro (3, 42, 45), although we have 
previously shown that deletion of this region of dystrophin 
has no effect on localization of syntrophin or the assembly 
of the DAP complex and produces a fully functional dys- 
trophin protein in young transgenic/mdx mice (39). These 
data, together with the fact that mutations in the known 
DAP members cannot account for several forms of limb 
girdle muscular dystrophy, suggest that other members of 
the DAP complex remain to be identified. In addition, in 
vitro data may not provide a complete picture with which 
to predict endogenous protein function, thus underscoring 
the importance of an in vivo approach. 
We have previously shown that expression of the cys- 
teine-rich and COOH-terminal domains of dystrophin in 
the skeletal muscle of transgenic/mdx mice is able to re- 
store proper localization of all members of the DAP com- 
plex, but is unable to prevent the dystrophic phenotype in 
these  mice  (12,  17).  In the  present study, we  generated 
transgenic/mdx  mice  that  express  full-length  dystrophin 
constructs deleted for consecutive regions of the COOH 
terminus to enable an in vivo analysis of the function of 
the dystrophin COOH terminus and to determine how it 
interacts with the members of the DAP complex. 
Materials and Methods 
Dystrophin Deletion Transgenes 
All deletions were constructed by recombinant PCR using the routine full- 
length dystrophin cDNA as a template (26). Although exon numbers were 
used to name these constructs, the extent of each deletion does not pre- 
cisely follow exon boundaries. A64-67 deletes amino acids 3145-3300,  A68- 
70 deletes amino acids 3301-3443,  and A75-78 deletes amino acids 3570- 
3717,  leaving the last three amino acids of the mouse dystrophin protein 
intact (9). A65-66 is a precise deletion of exons 65 and 66, based on the 
mdx  3cv mutation (11). A71-74 precisely deletes these exons and has been 
described previously (39). Dystrophin constructs were cloned into expres- 
sion vectors containing the -3300 mouse muscle creatine kinase promoter 
and enhancer elements, either a VPI intron from the pSVL plasmid (Phar- 
macia Fine Chemicals, Piscataway, NJ)  (A64-67 and A65-66) or the syn- 
thetic minx intron derived from adenovirus (31),  as well as the SV-40 
polyadenylation site. 
Generation of Transgenic Mice 
Wild-type hybrid embryos from C57B1/6J SJL/J were injected with dystro- 
phin expression vectors as previously described (20) (A64-67, A65-66, and 
A68-70).  F0 mice were screened by PCR with primers to the mouse dys- 
trophin cDNA. Positive transgenic mice were bred onto an mdx null dys- 
trophin background for analysis. The A75-79  transgene was injected di- 
rectly into C57B1/10J mdx x  (SJL/J x  C57BI/10J mdx) embryos to reduce 
the number of generations of breeding needed to obtain animals on the 
mdx background for analysis. The females used for superovulation to pro- 
duce these embryos were 4 wk old and weighed between 10 and 12 g. 
Western Analysis 
Total protein was extracted from the quadriceps of control and transgenic 
mice, and protein concentrations were determined using the Coomassie 
Plus Protein Assay Reagent (Pierce Chemical Co., Rockford, IL). 100 p.g 
of each sample was electrophoresed  on a  6%  polyacrylamide/SDS gel 
(29.7:0.3 acryl/bis), transferred for 2 h at 75 V onto Biotrace Nitrocellulose 
(Gelman Science,  Ann Arbor  MI)  in  1 X  Tris-glycine, 20%  methanol, 
0.05%  SDS,  using a  wet-transfer  apparatus  (Hoefer  Scientific  Instru- 
ments, San Francisco, CA). Membranes were blocked in 10% nonfat dry 
milk, 1% normal goat serum, and 0.1% Tween 20, and hybridized with 
DYS1 (Novacastra, Newcastle, UK) at a 1/1,000  dilution for 2 h at room 
temperature, washed, and then probed with HRP-conjugated anti-mouse 
antibodies at a 1/2,000 dilution (Cappel Laboratories, Durham, NC). Blots 
were developed using the ECL chemiluminescence system (Amersham, 
Arlington Heights, IL). All incubations contained 1% normal goat serum 
and 0.1% Tween 20. 
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New Zealand White rabbits were injected subcutaneously with gel-puri- 
fied, bacterially expressed recombinant protein containing the first 423 
amino acids of murine dystrophin fused to the FLAG peptide (IBI). Initial 
injections were with 500/xg of protein mixed 1:1 (vol/vol) with Freund's 
complete adjuvant. Rabbits were boosted eight times at ~4 wk intervals 
with 100-300  p,g of the fusion protein mixed 1:1 (vol/vol) with Freund's in- 
complete adjuvant. Serum was obtained 11 d after the eighth booster in- 
jection. 
To affinity purify the rabbit antidystrophin antibodies, a bacterially ex- 
pressed fusion protein containing the first 246 amino acids of murine dys- 
trophin fused to the maltose-binding protein was purified according to the 
manufacturer's instructions  (New England  Biolabs, Beverly, MA)  and 
coupled to  a  glutaraldehyde-preactivated Acti-Disk 25  according to the 
manufacturer's instructions (Whatman  Chemical Co.,  Clifton, NJ).  Im- 
mune serum was chromatographed over the disk,  washed with PBS, fol- 
lowed by PBS containing 1 M NaC1. Antibodies were eluted with 0.1 M gly- 
cine-HCl, pH  2.8,  into  a  tube  containing  0.25  vol  of  1  M  Tris.  The 
antibodies were concentrated and resuspended in PBS with a Centricon- 
30 concentrator (Amicon, Inc., Beverly, MA). 
Immunohistochemistry 
Skeletal muscle was removed from control and transgenic animals, cut 
into strips, embedded in Tissue-tek OCT mounting media (Miles, Inc.), 
and frozen quickly in liquid nitrogen-cooled isopentane. 7-p~m sections 
were blocked with 1% gelatin in KPBS for 15 rain, washed in KPBS  + 
0.2% gelatin (KPBSG), and incubated for 2 h in KPBSG  +  1% normal 
goat serum with each affinity-purified primary antibody at the following 
dilutions:  dystrophin NH2  terminus  1/1,300,  13-dystroglyean  1/200 (21), 
syntrophin 1/15 (this polyclonal antibody recognizes all three members of 
the syntrophin triplet on Western analysis, but cross-reactivity with indi- 
vidual isoforms has not been further characterized [33, 45]), o~-sarcoglycan 
1/20 (40), and 3,-sarcoglycan  1/5 (22). After washing, the slides were incu- 
bated for 1 h with either biotin-labeled goat anti-rabbit polyclonal anti- 
bodies (for dystrophin, 13-dystroglyean,  and a-sarcoglycan; Pierce) or bi- 
otin-labeled donkey anti-sheep polyclonal antibodies (for syntrophin and 
~/-sarcoglycan;  Sigma Immunochemicals, St.  Louis, MO)  washed again, 
and  incubated  with FITC-conjugated  streptavidin.  After a  final  wash, 
Vectashield (Vector Laboratories, Burlingame, CA) with 4,6-diamidino- 
2-phenylindole  (DAPI)  was  applied  and  sections were  photographed 
through a dual bandpass filter (Chromatek) under 50× magnification us- 
ing an Optiphot-2 microscope (Nikon Inc., Melville, NY). 
Histology 
Skeletal muscle was removed from control and transgenic animals, cut 
into strips, and fixed overnight at 4°C in 3.5% formaldehyde/0.5% glu- 
taraldehyde. The  sections were dehydrated in  70%  ethanol, incubated 
overnight in glycol methacrylate (GMA) reagents, and embedded in liq- 
uid GMA that was subsequently polymerized. 4-~m sections of the tissue- 
containing GMA blocks were affixed to slides and stained with hematoxy- 
lin and eosin. 
Results 
We generated transgenic/rndx mice that express full-length 
dystrophin constructs deleted for consecutive regions of 
the COOH terminus to analyze the function of the dystro- 
phin COOH terminus and how it interacts with the mem- 
bers of the DAP complex (Fig. 1). Transgene constructs 
were either injected directly into mdx embryos or onto a 
wild-type background that required breeding of positive 
transgenic animals onto an mdx background for analysis. 
Total protein  extracts of quadriceps  muscles  from each 
transgenic/mdx line  were  analyzed by Western  analysis 
with an antibody raised against the rod domain of dystro- 
phin (Fig. 2). Each transgenic/mdx line produced a single 
isoform of dystrophin in muscle that corresponded to the 
deletion construct used to generate the line. No degrada- 
tion products were observed for any of the dystrophin de- 
letion proteins, suggesting that all proteins were being sta- 
bly produced at levels sufficient for correction in the case 
of a functional dystrophin protein (except for the A65-66 
line, see below). This latter conclusion is derived from pre- 
vious observations indicating that 20-30%  of normal dys- 
trophin levels are sufficient to prevent dystrophic pathol- 
ogy in mdx mice (37, 43). In addition, the A64-67 mice and 
the  A75-78 mice  accumulate  similar  dystrophin  levels 
(Figs. 2 and 3), and the latter line of mice displays no pa- 
thology (see below). To determine the effect of each of the 
Figure  1.  Diagram  of  the 
transgenes  used  to  generate 
dystrophin  COOH-terrninal 
deletion  proteins  in  mdx 
mice.  The  MDA  full-length 
dystrophin  construct  (10) 
and the Dp71  COOH-termi- 
nal dystrophin construct (12) 
are shown as a  reference for 
the position of the deletions 
in the full-length COOH-ter- 
minal  deletion  transgenes. 
The -3300 muscle creatine ki- 
nase  (MCK)  promoter  and 
either the VPI or minx intron 
was  used  to  express each  of 
the COOH-terminal deletion 
dystrophin proteins. An SV-40 
poly A  addition  site  was  in- 
serted downstream from each 
dystrophin  cDNA.  COOH- 
terminal  domains  and  exon 
numbers are labeled. 
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ity-purified mAb raised against the rod domain of dystrophin  de- 
tects the 427-kD protein in control (C57B1/10) quadriceps  muscle 
and the truncated dystrophin  proteins produced in each of the 
transgenic  lines. No dystrophin  protein is detected in  extracts 
from mdx quadriceps muscle. 
Deletion of Exons 64-67 
The A64-67  construct is deleted for the region of homol- 
ogy with  the  cysteine-rich  region  of  [3-spectrin  (Fig.  1). 
Only one line of transgenic mice with this construct dis- 
played expression  of the  transgene,  and  this  expression 
was observed only in limb muscles at levels N50% of wild- 
type  expression  (Fig.  2).  Localization  of  [3-dystroglycan 
and  all members of the  sarcoglycan complex at the  sar- 
colemmal membranes of mice expressing the  A64-67  dys- 
trophin protein is reduced to levels equal to or less than 
those present in mdx mice (Fig.  3).  ed-syntrophin,  how- 
ever, is present at levels similar to that of the dystrophin 
deletion protein. A64-67 was unable to function to prevent 
the development of a dystrophic pathology. Skeletal mus- 
cle from these mice was characterized by patches of necro- 
sis and fibrosis larger than those seen in age-matched mdx 
mice (Fig. 5). 
deletions on dystrophin localization, as well as the unifor- 
mity of expression of each of the deleted proteins, trans- 
genic/mdx  mice were analyzed by immunohistochemistry. 
Each of the deleted dystrophin proteins properly localized 
to the sarcolemmal membrane (Fig. 3). 
Proper localization and accumulation of the members of 
the DAP complex has been shown to be disrupted in mdx 
mice (33).  We have previously shown that expression of 
the COOH terminus of dystrophin (Dp71), which consists 
of exons 63-79 (Fig. 1), is able to restore proper localiza- 
tion of the members of the DAP complex (12). To deter- 
mine the effect of the consecutive COOH-terminal dele- 
tions  of  dystrophin  on  the  localization  of  the  DAPs, 
immunohistochemical analysis was carried out on quadri- 
ceps sections from 3-mo-old transgenic/mdx  animals using 
antibodies to each of the identified members of the dystro- 
glycan, sarcoglycan, and syntrophin subcomplexes. 
Skeletal muscle from 3-too-old mdx mice is also charac- 
terized by a high percentage of central nuclei, which is in- 
dicative  of rounds  of degeneration  and  regeneration  of 
muscle fibers, as well as infiltration  of small necrotic re- 
gions with macrophages and a progressive accumulation of 
connective tissue, particularly in the diaphragm. To deter- 
mine the effect that each of the COOH-terminal deletion 
dystrophin  proteins had  on the  dystrophic phenotype of 
the mdx mouse, fixed quadriceps sections from 3-mo-old 
transgenic/mdx  mice  from  each  uniform  expressing  line 
were  stained  with  hematoxylin  and  eosin  to  assess  the 
function  of  the  dystrophin-associated  complex  that  was 
formed with each deletion protein. In addition, the quadri- 
ceps  sections  analyzed  by  immunohistochemistry  were 
counterstained  with the  DNA dye DAPI to  observe the 
presence of central nuclei within the myofibers. 
Deletion of Exons 65-66 
The  A65-66  construct  corresponds  to  the  major  spliced 
form of dystrophin observed in the mdx  3cv mouse (12). It 
was not known whether the dystrophic pathology seen in 
these mice was caused by the extremely low levels of pro- 
tein produced, or whether this protein was nonfunctional. 
The  only  transgenic  lines  expressing  this  construct  dis- 
played  a  mosaic pattern  of expression,  making  a  direct 
analysis of the function of this deleted protein impossible 
(Fig.  3).  These  mosaic-expressing  mice,  however,  were 
able to be analyzed for proper localization of the members 
of the DAP complex. To establish that formation of the 
dystroglycan complex is independent  of uniform dystro- 
phin expression, we analyzed the pattern of [3-dystrogly- 
can localization in a line of mice with mosaic expression of 
the  A71-74  dystrophin  protein,  which  we  have  already 
shown to interact normally with  all of the  DAPs. These 
mice show a mosaic pattern of localization of [3-dystrogly- 
can,  similar  to  that  observed  for  dystrophin  (data  not 
shown).  This  result  shows  that  the  localization  of  the 
DAPs in a fiber is dependent only on expression of dystro- 
phin in that same fiber, and that no higher order structure 
between fibers is needed for the formation of the dystro- 
phin-glycoprotein  complex.  B-dystroglycan  (Fig.  3)  and 
the members of the sarcoglycan complex (Fig. 4) were all 
observed to be greatly reduced at the sarcolemmal mem- 
brane of transgenic/mdx  mice expressing the  A65-66  dys- 
trophin  protein,  compared with control animals.  In con- 
trast, syntrophin was present in a similar mosaic pattern as 
dystrophin expression (Fig. 3). We thus conclude that the 
A65-66  protein  cannot  associate  with  the  dystroglycan 
complex, and is therefore unlikely to be functional. 
Figure 3.  Immunostaining of quadriceps  muscle sections from control,  mdx, and transgenic/mdx mice with antibodies  against dystro- 
phin, [3-dystroglycan,  and syntrophin. All truncated dystrophin proteins localize normally to the sarcolemma.  [3-dystroglycan and syntro- 
phin colocalize with dystrophin in control animals and are greatly reduced in mdx fibers. Syntrophin is present at the sarcolemmal mem- 
brane of fibers from all transgenic/mdx lines. [3-dystroglycan localization  at the sarcolemma is reduced to levels equal to or less than 
those present in mdx fibers in all transgenic/mdx lines containing  a deletion in the cysteine-rich domain, but is normal in A71-74/mdx, 
and A75-78/mdx lines. All photographs were taken at the same exposure. Bar, 100 ixm. 
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ceps  muscle  sections  from  control, 
mdx,  and transgenic/rndx  mice with 
antibodies against c~- and ~/-sarcogly- 
can.  c~- and "y-sarcoglycan colocalize 
with  dystrophin  in  control  animals 
and  with  truncated  dystrophin  pro- 
teins that are able to correct the mdx 
phenotype.  Both  proteins  are  re- 
duced at the sarcolemmal membrane 
in rndx mice and transgenic/mdx lines 
containing cysteine-rich domain dele- 
tions. All photographs were taken at 
the same exposure. Bar, 100 Ixm. 
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The A68-70 construct is deleted for the region of dystro- 
phin containing the second half of the cysteine-rich domain 
(Fig. 1). Expression of the transgene in these mice results 
in essentially wild-type levels of dystrophin in quadriceps 
muscles  (Fig.  2).  The  A68-70  mice show a  reduction in 
levels of ~-dystroglycan, a-, and ~/-sarcoglycan at the sar- 
colemmal membrane equivalent to that seen in mdx skele- 
tal  muscle  (Figs.  3  and  4).  In  contrast,  syntrophin  lo- 
calization is unaffected in these mice (Fig. 3). The A68-70 
protein is also unable to prevent the phenotype of the mdx 
mouse, suggesting again the importance of the interaction 
of dystrophin with the dystroglycan and sarcoglycan com- 
plexes (Fig. 5). 
Deletion of Exons 71-74 
As we have previously reported, deletion of the alterna- 
tively spliced  domain  and  disruption  of the first leucine 
zipper motif, A71-74  (previously referred to as A330), has 
no effect on the function of dystrophin (39). We have now 
observed that  this  dystrophin deletion protein functions 
completely normally up  to  at  least 2  yr of age  (Rafael, 
J.A.,  and  J.S.  Chamberlain,  unpublished  observations). 
We have also previously shown that the A71-74 dystrophin 
protein  is  able  to  associate  with  some  members  of the 
DAP complex. To expand this analysis to the newly identi- 
fied members of the sarcoglycan complex, we used an anti- 
body to "v-sarcoglycan for immunohistochemical analysis 
of quadriceps sections from these same mice. All of the 
known DAP complex members were observed to associate 
normally with the A71-74 dystrophin protein (Figs. 3--5). 
Deletion of Exons 75-78 
The A75-78 construct is deleted for the second leucine zip- 
per motif and all except the final three amino acids of the 
COOH  terminus  of  dystrophin.  Multiple  lines  of mice 
showed expression of this transgene in either diaphragm 
or quadriceps muscles or in both. The A75-78  dystrophin 
protein is also able to localize correctly all of the members 
of the DAP complex and was able to prevent the appear- 
ance of any dystrophic symptoms in 3-mo-old transgenic/ 
mdx mice (Figs. 3-5). 
Discussion 
Although efforts are being made to develop treatments for 
patients with DMD, the primary pathogenesis leading to 
this disease is not fully understood. By studying structure- 
function correlations of the critical COOH-terminal domain 
of dystrophin, we may achieve a greater understanding of 
the  degenerative process  seen  in  DMD.  Previously, we 
showed that expression only of the dystrophin COOH-ter- 
minal region (Dp71) in skeletal muscles of mdx mice sup- 
ported normal assembly of the DAP complex, but the dys- 
trophic  pathology  was  not  prevented,  indicating  that 
amino-terminal dystrophin sequences are also required for 
dystrophin function (12). To explore the COOH-terminal 
domains  in  the  context of an  otherwise fully functional 
dystrophin, we  have now generated transgenic mice ex- 
Figure 5.  Morphology of quadriceps sections from control, mdx, 
and transgenic/mdx mice. Haematoxylin and eosin staining  of 
4-1xm fixed sections from 3-mo-old mice shows a high percentage 
of central nuclei and patches of necrosis and fibrosis in mdx and 
transgenic/mdx animals where the truncated dystrophin protein is 
not able to associate with the dystroglycan and sarcoglycan com- 
plexes. A71-74/mdx and  A75-78/mdx quadriceps  sections do not 
show signs of any dystrophic pathology. 
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consecutive regions of the COOH terminus of dystrophin. 
Our data show that the cysteine-rich region of dystrophin 
is critical for interacting with the DAP complex in vivo, 
and that disruption of this interaction alone is able to ren- 
der a membrane-localized, full-length dystrophin protein 
completely nonfunctional. In contrast, deletions of the al- 
ternatively spliced region and the extreme COOH termi- 
nus have no apparent effect on the function of dystrophin. 
Both of these latter dystrophin proteins are able to associ- 
ate properly with all known DAP complex members. 
These transgenic  studies provide information about  a 
region of dystrophin that was not well understood from 
studies of patient data. Most DMD patients with COOH- 
terminal deletions have undetectable levels of dystrophin 
protein,  making  structure-function  studies  impossible. 
Few patients have been described that contribute to an un- 
derstanding of the dystrophin COOH terminus. One pa- 
tient (patient CM)  has a  deletion of exons 72-79 that is 
predicted to make a  truncated protein (30). This patient 
has a very mild BMD phenotype, although it is not known 
at what level the truncated protein is expressed. We have 
deleted this region in two parts, and have shown that both 
deleted proteins support normal muscle development and 
function when expressed near normal levels. A second re- 
ported patient has a deletion of exons 64-78 that encom- 
passes the  13-dystroglycan-binding domain in addition to 
the remainder of the COOH terminus (5, 19). This patient 
displays a mosaic expression pattern, and multiple degra- 
dation products of the truncated dystrophin protein were 
observed by Western analysis. The patient with the exon 
64-78 deletion is very severely affected, as are the Dp71 
(12) and the  A64-67  transgenic mice (Fig. 5), suggesting 
that the presence on the sarcolemmal membrane of a non- 
functional dystrophin protein is more deleterious than a 
lack  of dystrophin expression.  It  is  possible  that  either 
utrophin  or  the  87-kD  dystrophin-like  phosphoprotein 
(dystrobrevin), which have both been shown to bind some 
of the DAPs in vitro (3, 6, 45), are able to compensate par- 
tially for dystrophin in its absence. A  nonfunctional dys- 
trophin localized to the sarcolemmal membrane, however, 
may out-compete such interactions. 
Our in vivo data,  in combination with recent in vitro 
binding assays between dystrophin and some members 
of the DAP complex, supports a model for the structure 
of this complex. The in vitro binding studies suggest that 
~-dystroglycan may be the only member of the dystrogly- 
can and sarcoglycan complexes that binds directly to dys- 
trophin. 13-dystroglycan  is able to bind to fusion proteins 
containing only exons 63-67 of dystrophin, but this binding 
appears to be enhanced by protein sequences contained 
within  exons 68-70  of dystrophin (23, 41).  This in  vitro 
data is supported by our in vivo evidence. The A68-70 line 
appears less affected than the A64-67 line. This observa- 
tion suggests that the low level of 13-dystroglycan  in A68-70 
mice may be able to form partially functional complexes 
via binding to the exon 64-67 region of dystrophin. Inter- 
estingly, the critical region between exons 63-67 represents 
the  COOH-terminal  extent  of  the  conserved  region 
among dystrophin, a-spectrin,  and  a-actinin  (25).  While 
the exon 68-70 region is not conserved with these latter 
proteins, it does contain a zinc finger-like motif that could 
participate in strengthening the interaction with 13-dystro- 
glycan (38). 
Results  from  the  A64-67  mice,  together  with  patient 
data, implies that the sarcoglycan complex associates with 
dystrophin via 13-dystroglycan.  Studies of LGMD patients 
has revealed that LGMD types 2D, 2E, and 2C are caused 
by defects in a-, 13-, and ~/-sarcoglycan, respectively (8, 22, 
27,  28,  32).  In  each  of these  sarcoglycanopathies, defi- 
ciency of one sarcoglycan protein results in the absence of 
each of the remaining two sarcoglycan proteins, indicating 
that  these  proteins  are  mutually dependent  on  one an- 
other for stability. The absence of the sarcoglycans do not, 
however, affect the stability or localization of either dys- 
trophin or dystroglycan. Nonetheless, a complete absence 
of either dystrophin, or the sarcoglycans leads to a severe, 
DMD-like phenotype. Our data indicate that the absence 
of a  direct  link  between  dystrophin and  13-dystroglycan 
similarly leads to the absence of the sarcoglycan proteins 
and a severe phenotype. Thus, even though no human dis- 
eases have been observed to result from the  absence of 
dystroglycan, our data indicate that defective expression 
of dystrophin, dystroglycan, or the sarcoglycans is incom- 
patible with normal muscle function. 
al-syntrophin is highly expressed in skeletal muscle and 
displays  an  identical  localization  pattern  to  dystrophin 
(36). Both al-syntrophin and 131-syntrophin,  the latter ex- 
pressed predominantly in liver but at moderate levels in 
skeletal muscle, have been shown to bind the exon 73-74 
regions of dystrophin in vitro (3, 42, 45). The deletion of 
these exons in vivo does not affect the proper localization 
of syntrophin (reference 39 and Fig. 4). The A71-74 pro- 
tein is also completely functional in mdx mice, suggesting 
that these exons are not critical for dystrophin function in 
skeletal muscle. It is possible that these exons, which are 
alternatively spliced in nonskeletal muscle tissues such as 
brain and cardiac muscle, are involved in modulating the 
interaction between dystrophin isoforms and the syntro- 
phins in these tissues. 
The  normal  expression  pattern  of syntrophin  in  the 
A71-74 mice indicates that there must be additional factors 
involved in the localization of the syntrophins. One possi- 
bility is that ~1 and/or 131-syntrophin binds to a member of 
the  dystroglycan or sarcoglycan complexes and that this 
association leads to the proper localization of syntrophin 
in the A71-74 mice. Another alternative is that syntrophin 
binds as a homo- or hetero-dimer to dystrophin, both to 
the exon 71-74 region and perhaps weakly to a region else- 
where in dystrophin, possibly exons 75-78. Yang et al. (45) 
have shown that  al-syntrophin is  able  to bind  all three 
syntrophin isoforms in vitro, suggesting that dimer or tri- 
mer formation is  possible  in  vivo. Although  syntrophin 
was not found to bind to a  downstream region in vitro, 
such an interaction could occur in vivo. Finally, syntrophin 
that is bound to dystrophin may also interact with addi- 
tional partners  that  could help anchor it into the  DAP 
complex (Fig. 6). Support for this latter hypothesis comes 
from the observation that protein A0 copurifies with the 
syntrophin subcomplex  (41),  and  A0  has  recently been 
identified as an isoform of dystrobrevin (6, 46). Neuronal 
nitric oxide synthase has recently been shown to bind al- 
syntrophin in type II muscle fibers via conserved PDZ do- 
mains (7), although nNOS may only bind a subset of the 
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teraction of dystrophin-asso- 
ciated  proteins  with  the 
COOH  terminus  of dystro- 
phin, based on in vitro and in 
vivo data.  The  dystroglycan 
and  sarcoglycan  (SG)  pro- 
teins require the COOH-ter- 
minal portions of dystrophin 
encoded on exons 64-67 for 
assembly  and  stability.  Re- 
moval  of  dystrophin  exons 
68-70  also  destabilizes  the 
dystroglycan and sarcoglycan 
complexes but to a lesser de- 
gree,  as  evidenced  by  the 
milder phenotype of mdx an- 
imals  expressing  the  A68-70 
construct,  as  compared with 
mdx  mice  expressing  the 
A64-67 construct (Figs.  3-5). 
These  observations are  con- 
sistent  with a model in which 
the  sarcoglycan proteins  do 
not directly bind dystrophin, 
but  are  dependent  on  the 
[3-dystroglycan--dystrophin in- 
teraction for stability  and as- 
sociation with the complex. Syntrophin (SYN) isoforms in vitro are able to bind themselves and to the portion of dystrophin encoded 
by exons 73-74, but association of ctl-syntrophin with the dystrophin complex is stable in the absence of these exons in vivo (Fig. 3). 
These observations suggest that a direct interaction between syntrophin and another protein can stabilize  the localization of syntrophin 
and allow normal muscle function in the absence of a direct link with dystrophin. This additional interaction might be with another 
member of the DAP complex, with other syntrophin isoforms, with dystrophin bomologues such as dystrobrevin, or with PDZ domain 
containing proteins, including nitric oxide synthase (NOS), some of which might link syntrophin to the membrane or to the subsar- 
colemmal cytoskeleton. Question marks indicate hypothetical interactions. 
DAP complexes in these fibers. Syntrophin might also in- 
teract  with  additional  PDZ  domain  proteins  to  form  at- 
tachments  either  to membrane-bound  DAPs  or to other 
components of the subsarcolemmal cytoskeleton (Fig. 6), 
Through any of these mechanisms, syntrophin isoforms 
would still be able to form a functional interaction with the 
DAP complex,  even in  the  absence  of a  direct  link  with 
dystrophin.  It  is  possible  that  syntrophin  plays  a  funda- 
mentally  distinct  role  in  the  DAP  complex  than  do  the 
dystroglycan and  sarcoglycan proteins.  This  role  may be 
distinct from the primary structural role of the DAP com- 
plex in linking the subsarcolemmal cytoskeleton to the ex- 
tracellular  matrix.  One possibility is that  syntrophin may 
play more of a regulatory role, modulating the interaction 
between  the  remaining  DAP  members,  or  between  the 
DAP complex and the cytoskeleton, in response to varying 
physiological states of the muscle fibers. 
Other protein interactions could also be occurring in the 
COOH-terminal regions of dystrophin. The A75-78 region 
contains a  leucine zipper motif that has been observed to 
bind troponin T  in the yeast two-hybrid system (35).  Dis- 
ruptions of this leucine zipper motif and the one encoded 
in exons 74-75, however, appear  to have no effect in our 
transgenic mice. Aciculin has also been shown to associate 
with  dystrophin  in  a  muscle  cell  line  (4).  However,  this 
protein has not been shown to be the primary defect in any 
muscular dystrophy, nor is it clear whether it binds to dys- 
trophin or a to member of the DAP complex. 
The analysis of transgenic/rndx  mice expressing dystro- 
phin  proteins  with  consecutive  deletions  of the  COOH- 
terminal region has provided insight into the formation of 
the dystrophin-associated protein complex and the patho- 
genesis of DMD. This study provides additional in vivo ev- 
idence  that  a  critical  function  of  dystrophin  in  skeletal 
muscle is to provide a link to the DAP complex via a direct 
association  with  13-dystroglycan.  Severing  this  link  via 
small  deletions  in  the  cysteine-rich  domain,  without  dis- 
rupting  the  remainder  of  the  dystrophin  molecule,  is 
enough  to  lead  to  the  severe  muscle  pathology seen  in 
DMD.  In contrast,  a  direct  link  between  dystrophin  and 
syntrophin  does not appear critical for prevention  of the 
dystrophic pathology observed in DMD and in rndx mice. 
A  complete understanding of the formation of the dystro- 
phin-associated protein complex will help to provide a ba- 
sis for a greater understanding of muscular dystrophies. 
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